Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07619339CT.gov A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06908993CT.gov Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated | — | Recruiting | — | — | — |
NCT06031688CT.gov Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | — | Recruiting | — | — | — |
NCT06083857CT.gov PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT06106802CT.gov Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment | — | Recruiting | — | — | — |
NCT05782361CT.gov POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC | — | Active Not Recruiting | — | — | — |
NCT04739358CT.gov CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC | — | Terminated | — | — | — |
NCT04591431CT.gov The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | — | Unknown | — | — | — |
NCT03940703CT.gov A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | — | Active Not Recruiting | — | — | — |
NCT02864992CT.gov Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) | — | Active Not Recruiting | — | — | — |
Show 1 more trialShow fewer
NCT01982955CT.gov Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tepotinib (this asset) | Memorial Sloan Kettering Cancer Center | P3 | B · 63 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Tepotinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer | — | P2 | CCC · 55 |
| Lung Adenocarcinoma | — | P2 | CCC · 53 |
| Hematopoietic And Lymphoid System Neoplasm | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tepotinib in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tepotinib-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →